Competition Bureau completes preliminary investigation concerning relabelled biologic drugs
The Competition Bureau has completed a preliminary investigation into potential anticompetitive harm from relabelled biologic drugs, and has closed that investigation because the drugs in question have not been marketed in...To view the full article, register now.
Already a subscriber? Click here to view full article